CLL Archives -

AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatment

https://pharmaphorum.com/news/az-msd-parp-inhibitor-ovarian-cancer/

AZ prepares for showdown with AbbVie/J&J as Calquence shines in CLL

https://pharmaphorum.com/news/az-prepares-for-showdown-with-abbvie-jj-as-calquence-shines-in-cll/

Roche and AbbVie’s Venclexta approved in CLL

https://pharmaphorum.com/news/roche-and-abbvies-venclexta-approved-in-cll/

AbbVie/Roche seek first-line CLL use for Venclexta combo

https://pharmaphorum.com/news/abbvie-roche-seek-first-line-cll-use-for-venclexta-combo/

AbbVie and J&J claim new Imbruvica okay in US

https://pharmaphorum.com/news/abbvie-and-jj-claim-new-imbruvica-okay-in-us/

Roche’s Mabthera faces cut-price competition in EU

https://pharmaphorum.com/news/roches-mabthera-faces-cut-price-competition-eu/

AbbVie’s Venclyxto approved in Europe in CLL

https://pharmaphorum.com/news/abbvies-venclyxto-approved-europe-cll/

AbbVie’s CLL drug recommended in Europe

https://pharmaphorum.com/news/eu-regulators-back-abbvie-drug-cll/

NICE rejects Roche drug in follicular lymphoma

https://pharmaphorum.com/news/nice-rejects-roche-drug-follicular-lymphoma/

Search